JP2004508357A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004508357A5 JP2004508357A5 JP2002525110A JP2002525110A JP2004508357A5 JP 2004508357 A5 JP2004508357 A5 JP 2004508357A5 JP 2002525110 A JP2002525110 A JP 2002525110A JP 2002525110 A JP2002525110 A JP 2002525110A JP 2004508357 A5 JP2004508357 A5 JP 2004508357A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- phenyl
- pyrrolidin
- compound according
- quinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000008589 Obesity Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- -1 methylenedioxy Chemical group 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229940086609 Lipase inhibitor Drugs 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 2
- 229960001243 orlistat Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- PBTSUCHVZHEYFX-UHFFFAOYSA-N 1-[3-(2-methyl-4-pyrrolidin-1-ylquinazolin-7-yl)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2C=C3N=C(C)N=C(C3=CC=2)N2CCCC2)=C1 PBTSUCHVZHEYFX-UHFFFAOYSA-N 0.000 claims 1
- WLHTVHLJGMWRLP-UHFFFAOYSA-N 1-[4-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 WLHTVHLJGMWRLP-UHFFFAOYSA-N 0.000 claims 1
- SVQUONYNVYWPAQ-UHFFFAOYSA-N 1-[5-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)thiophen-2-yl]ethanone Chemical compound S1C(C(=O)C)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 SVQUONYNVYWPAQ-UHFFFAOYSA-N 0.000 claims 1
- ZEHYSJACCJZZFU-UHFFFAOYSA-N 2-methoxy-4-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)phenol Chemical compound C1=C(O)C(OC)=CC(C=2C=C3N=C(C)C=C(C3=CC=2)N2CCCC2)=C1 ZEHYSJACCJZZFU-UHFFFAOYSA-N 0.000 claims 1
- ZKDKANVEYYIOHT-UHFFFAOYSA-N 2-methyl-4-piperidin-1-yl-7-[3-(trifluoromethyl)phenyl]quinoline Chemical compound C=12C=CC(C=3C=C(C=CC=3)C(F)(F)F)=CC2=NC(C)=CC=1N1CCCCC1 ZKDKANVEYYIOHT-UHFFFAOYSA-N 0.000 claims 1
- YHOOHRCDOSVZAJ-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-7-[3-(trifluoromethyl)phenyl]quinazoline Chemical compound C=12C=CC(C=3C=C(C=CC=3)C(F)(F)F)=CC2=NC(C)=NC=1N1CCCC1 YHOOHRCDOSVZAJ-UHFFFAOYSA-N 0.000 claims 1
- GWRLSUAPTXQGQZ-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-7-[3-(trifluoromethyl)phenyl]quinoline Chemical compound C=12C=CC(C=3C=C(C=CC=3)C(F)(F)F)=CC2=NC(C)=CC=1N1CCCC1 GWRLSUAPTXQGQZ-UHFFFAOYSA-N 0.000 claims 1
- QHMXVJPBDHKSNO-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-7-thiophen-2-ylquinoline Chemical compound C=12C=CC(C=3SC=CC=3)=CC2=NC(C)=CC=1N1CCCC1 QHMXVJPBDHKSNO-UHFFFAOYSA-N 0.000 claims 1
- DVUXOKQEIGQWDI-UHFFFAOYSA-N 2-methyl-7-naphthalen-2-yl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=C4C=CC=CC4=CC=3)=CC2=NC(C)=CC=1N1CCCC1 DVUXOKQEIGQWDI-UHFFFAOYSA-N 0.000 claims 1
- OXHZRYAWIMZYBS-UHFFFAOYSA-N 2-methyl-7-pyridin-3-yl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=NC=CC=3)=CC2=NC(C)=CC=1N1CCCC1 OXHZRYAWIMZYBS-UHFFFAOYSA-N 0.000 claims 1
- VHRDDHZYCJGTHE-UHFFFAOYSA-N 3-(2-methyl-4-pyrrolidin-1-ylquinazolin-7-yl)benzonitrile Chemical compound C=12C=CC(C=3C=C(C=CC=3)C#N)=CC2=NC(C)=NC=1N1CCCC1 VHRDDHZYCJGTHE-UHFFFAOYSA-N 0.000 claims 1
- IBDGJNBACMWLOR-UHFFFAOYSA-N 4-(azepan-1-yl)-2-methyl-7-[3-(trifluoromethyl)phenyl]quinazoline Chemical compound C=12C=CC(C=3C=C(C=CC=3)C(F)(F)F)=CC2=NC(C)=NC=1N1CCCCCC1 IBDGJNBACMWLOR-UHFFFAOYSA-N 0.000 claims 1
- HNZFUPVFLZIPGY-UHFFFAOYSA-N 4-(azepan-1-yl)-2-methyl-7-[3-(trifluoromethyl)phenyl]quinoline Chemical compound C=12C=CC(C=3C=C(C=CC=3)C(F)(F)F)=CC2=NC(C)=CC=1N1CCCCCC1 HNZFUPVFLZIPGY-UHFFFAOYSA-N 0.000 claims 1
- DEHDCLRPFIWCER-UHFFFAOYSA-N 5-(3-chlorophenyl)-2-methyl-4-piperidin-1-ylquinoline Chemical compound C=12C(C=3C=C(Cl)C=CC=3)=CC=CC2=NC(C)=CC=1N1CCCCC1 DEHDCLRPFIWCER-UHFFFAOYSA-N 0.000 claims 1
- WKPACHADPWHREV-UHFFFAOYSA-N 7-(3,4-dichlorophenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=C(Cl)C(Cl)=CC=3)=CC2=NC(C)=CC=1N1CCCC1 WKPACHADPWHREV-UHFFFAOYSA-N 0.000 claims 1
- GGSPYNHXXJFFLS-UHFFFAOYSA-N 7-(3,5-dichlorophenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=C(Cl)C=C(Cl)C=3)=CC2=NC(C)=CC=1N1CCCC1 GGSPYNHXXJFFLS-UHFFFAOYSA-N 0.000 claims 1
- DTYNDESCRADOCW-UHFFFAOYSA-N 7-(3-chloro-4-fluorophenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=C(Cl)C(F)=CC=3)=CC2=NC(C)=CC=1N1CCCC1 DTYNDESCRADOCW-UHFFFAOYSA-N 0.000 claims 1
- FIQCWGFEPZLCIE-UHFFFAOYSA-N 7-(3-chlorophenyl)-2-methyl-4-pyrrolidin-1-ylquinazoline Chemical compound C=12C=CC(C=3C=C(Cl)C=CC=3)=CC2=NC(C)=NC=1N1CCCC1 FIQCWGFEPZLCIE-UHFFFAOYSA-N 0.000 claims 1
- MPAWSOPNRWJEAL-UHFFFAOYSA-N 7-(3-chlorophenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=C(Cl)C=CC=3)=CC2=NC(C)=CC=1N1CCCC1 MPAWSOPNRWJEAL-UHFFFAOYSA-N 0.000 claims 1
- ASAMDAHECQCGAB-UHFFFAOYSA-N 7-(4-methoxyphenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 ASAMDAHECQCGAB-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 238000006880 cross-coupling reaction Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229910052723 transition metal Inorganic materials 0.000 claims 1
- 150000003624 transition metals Chemical class 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00119262 | 2000-09-06 | ||
| PCT/EP2001/010014 WO2002020488A2 (en) | 2000-09-06 | 2001-08-30 | Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004508357A JP2004508357A (ja) | 2004-03-18 |
| JP2004508357A5 true JP2004508357A5 (enExample) | 2005-03-17 |
Family
ID=8169763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002525110A Pending JP2004508357A (ja) | 2000-09-06 | 2001-08-30 | キノリンおよびキナゾリン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6900226B2 (enExample) |
| EP (1) | EP1318981A2 (enExample) |
| JP (1) | JP2004508357A (enExample) |
| KR (1) | KR100621272B1 (enExample) |
| CN (1) | CN1274676C (enExample) |
| AR (1) | AR030596A1 (enExample) |
| AU (2) | AU1047402A (enExample) |
| BR (1) | BR0113710A (enExample) |
| CA (1) | CA2420703A1 (enExample) |
| GT (1) | GT200100183A (enExample) |
| MX (1) | MXPA03001928A (enExample) |
| PA (1) | PA8528401A1 (enExample) |
| PE (1) | PE20020485A1 (enExample) |
| UY (1) | UY26926A1 (enExample) |
| WO (1) | WO2002020488A2 (enExample) |
| ZA (1) | ZA200301719B (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60225274T2 (de) * | 2001-05-21 | 2009-03-26 | F. Hoffmann-La Roche Ag | Chinolinderivate als liganden für den neuropeptid-y-rezeptor |
| GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| NZ532427A (en) * | 2001-09-24 | 2008-07-31 | Imp Innovations Ltd | Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y) |
| US6787558B2 (en) | 2001-09-28 | 2004-09-07 | Hoffmann-La Roche Inc. | Quinoline derivatives |
| US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| ES2304498T3 (es) | 2002-02-04 | 2008-10-16 | F. Hoffmann-La Roche Ag | Derivados de quinolina como antagonistas de npy. |
| JP3813152B2 (ja) | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| WO2004005265A1 (en) | 2002-07-05 | 2004-01-15 | F. Hoffmann-La Roche Ag | Quinazoline derivatives |
| BR0313278A (pt) | 2002-08-07 | 2005-07-05 | Hoffmann La Roche | Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo e sua utilização, método para o tratamento e profilaxia de enfermidades e obesidade e utilização dos compostos |
| US7759336B2 (en) * | 2002-12-10 | 2010-07-20 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| US7166575B2 (en) * | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2004080463A1 (en) * | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
| KR20050122220A (ko) | 2003-03-25 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 디펩티딜 펩티다제 억제제 |
| US7579357B2 (en) | 2003-08-13 | 2009-08-25 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| CA2551037A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
| CA2545340A1 (en) | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
| MXPA06010571A (es) | 2004-03-15 | 2007-02-16 | Takeda Pharmaceutical | Inhibidores de dipeptidil peptidasa. |
| EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| US8283354B2 (en) * | 2004-09-02 | 2012-10-09 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| US7718658B2 (en) * | 2004-09-02 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| MX2007005408A (es) * | 2004-11-09 | 2007-05-16 | Hoffmann La Roche | Compuestos de aminoquinazolinas. |
| EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EP1892241B1 (en) | 2005-05-30 | 2016-03-30 | Msd K.K. | Novel piperidine derivative |
| GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| JPWO2007018248A1 (ja) | 2005-08-10 | 2009-02-19 | 萬有製薬株式会社 | ピリドン化合物 |
| US7875633B2 (en) | 2005-08-24 | 2011-01-25 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
| JPWO2007029847A1 (ja) | 2005-09-07 | 2009-03-19 | 萬有製薬株式会社 | 二環性芳香族置換ピリドン誘導体 |
| PL1942898T5 (pl) | 2005-09-14 | 2014-10-31 | Takeda Pharmaceuticals Co | Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy |
| WO2007035629A2 (en) | 2005-09-16 | 2007-03-29 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
| US20080255084A1 (en) | 2005-10-21 | 2008-10-16 | Randy Lee Webb | Combination of Organic Compounds |
| JPWO2007049798A1 (ja) | 2005-10-27 | 2009-04-30 | 萬有製薬株式会社 | 新規ベンゾオキサチイン誘導体 |
| WO2007055418A1 (ja) | 2005-11-10 | 2007-05-18 | Banyu Pharmaceutical Co., Ltd. | アザ置換スピロ誘導体 |
| US7678803B2 (en) * | 2006-08-24 | 2010-03-16 | Serenex, Inc. | Quinazoline derivatives for the treatment of cancer |
| US8027888B2 (en) * | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| WO2008038692A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| TWI428346B (zh) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| DK2170930T3 (da) | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
| EP2272841A1 (en) | 2008-03-28 | 2011-01-12 | Banyu Pharmaceutical Co., Ltd. | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
| EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2009154132A1 (ja) | 2008-06-19 | 2009-12-23 | 萬有製薬株式会社 | スピロジアミン-ジアリールケトオキシム誘導体 |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| JPWO2010013595A1 (ja) | 2008-07-30 | 2012-01-12 | Ｍｓｄ株式会社 | ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体 |
| JPWO2010035745A1 (ja) | 2008-09-25 | 2012-02-23 | 杏林製薬株式会社 | ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤 |
| WO2010041711A1 (ja) | 2008-10-09 | 2010-04-15 | 杏林製薬株式会社 | イソキノリン誘導体及びそれらを有効成分とするｐｄｅ阻害剤 |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| EP2362731B1 (en) | 2008-10-31 | 2016-04-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US20110230399A1 (en) * | 2008-11-25 | 2011-09-22 | Bowen Richard L | Methods for Treating Obesity Related Disease |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| SG192941A1 (en) | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| BR112014010644A2 (pt) | 2011-11-04 | 2017-04-25 | Hoffmann La Roche | novos derivados de aril-quinolina |
| WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| KR101415806B1 (ko) | 2012-08-22 | 2014-07-09 | 한국화학연구원 | 퀴놀린 유도체를 포함하는 골 질환의 예방 또는 치료용 약학적 조성물 |
| JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病二環式化合物 |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| BR112017003745A2 (pt) | 2014-08-29 | 2017-12-05 | Tes Pharma S R L | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico |
| US9353093B2 (en) | 2014-10-07 | 2016-05-31 | Allergan, Inc. | Indole-1-carboxamides as kinase inhibitors |
| JP2020500838A (ja) | 2016-10-14 | 2020-01-16 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | Α−アミノ−β−カルボキシムコン酸セミアルデヒドデカルボキシラーゼの阻害剤 |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| KR20210111248A (ko) | 2018-11-20 | 2021-09-10 | 테스 파마 에스.알.엘. | α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제 |
| CN109897874B (zh) * | 2019-03-25 | 2025-12-05 | 苏州同力生物医药有限公司 | 一种制备手性异喹啉羧酸的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4012513A (en) * | 1971-11-03 | 1977-03-15 | Imperial Chemical Industries Limited | Indole derivatives for providing analgesic and anti-inflammatory effects |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| JPH068292B2 (ja) | 1985-05-07 | 1994-02-02 | アルカロイダ ベギエスゼティ ギャル | トリアゾリルキノリン誘導体 |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| DK0556310T3 (da) * | 1990-11-06 | 1995-08-21 | Pfizer | Quinazolinderivater til forhøjelse af antitumoraktivitet |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| KR0144833B1 (ko) * | 1992-12-28 | 1998-07-15 | 김태훈 | 신규의 퀴나졸린 유도체 및 그의 제조방법 |
| EP0638567A4 (en) * | 1993-02-18 | 1995-05-10 | Kyowa Hakko Kogyo Kk | ADENOSINE INHIBITORS. |
| NZ318228A (en) | 1995-09-01 | 1999-07-29 | Lilly Co Eli | Indolyl neuropeptide y receptor antagonists |
| US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| EP1105123B1 (en) | 1998-08-14 | 2004-04-07 | F.Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors and chitosan |
| FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| AR028782A1 (es) * | 2000-07-05 | 2003-05-21 | Taisho Pharmaceutical Co Ltd | Derivados heterociclicos tetrahidropiridino o piperidino |
| DK1308439T3 (da) | 2000-08-10 | 2009-01-12 | Mitsubishi Tanabe Pharma Corp | Prolinderivater og anvendelse af disse som lægemidler |
| US6576644B2 (en) * | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
| SE0004054D0 (sv) * | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
| DE60225274T2 (de) * | 2001-05-21 | 2009-03-26 | F. Hoffmann-La Roche Ag | Chinolinderivate als liganden für den neuropeptid-y-rezeptor |
| US6787558B2 (en) * | 2001-09-28 | 2004-09-07 | Hoffmann-La Roche Inc. | Quinoline derivatives |
| ES2304498T3 (es) * | 2002-02-04 | 2008-10-16 | F. Hoffmann-La Roche Ag | Derivados de quinolina como antagonistas de npy. |
| WO2004002960A1 (en) * | 2002-06-27 | 2004-01-08 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
| WO2004005265A1 (en) * | 2002-07-05 | 2004-01-15 | F. Hoffmann-La Roche Ag | Quinazoline derivatives |
-
2001
- 2001-08-27 US US09/939,883 patent/US6900226B2/en not_active Expired - Fee Related
- 2001-08-30 WO PCT/EP2001/010014 patent/WO2002020488A2/en not_active Ceased
- 2001-08-30 JP JP2002525110A patent/JP2004508357A/ja active Pending
- 2001-08-30 BR BR0113710-7A patent/BR0113710A/pt not_active IP Right Cessation
- 2001-08-30 MX MXPA03001928A patent/MXPA03001928A/es not_active Application Discontinuation
- 2001-08-30 EP EP01978324A patent/EP1318981A2/en not_active Withdrawn
- 2001-08-30 KR KR1020037003252A patent/KR100621272B1/ko not_active Expired - Fee Related
- 2001-08-30 CA CA002420703A patent/CA2420703A1/en not_active Abandoned
- 2001-08-30 AU AU1047402A patent/AU1047402A/xx active Pending
- 2001-08-30 CN CNB018134610A patent/CN1274676C/zh not_active Expired - Fee Related
- 2001-08-30 AU AU2002210474A patent/AU2002210474B2/en not_active Ceased
- 2001-09-04 AR ARP010104191A patent/AR030596A1/es unknown
- 2001-09-04 PA PA20018528401A patent/PA8528401A1/es unknown
- 2001-09-05 PE PE2001000891A patent/PE20020485A1/es not_active Application Discontinuation
- 2001-09-05 GT GT200100183A patent/GT200100183A/es unknown
- 2001-09-05 UY UY26926A patent/UY26926A1/es not_active Application Discontinuation
-
2003
- 2003-02-28 ZA ZA200301719A patent/ZA200301719B/en unknown
-
2005
- 2005-04-07 US US11/100,938 patent/US7265125B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004508357A5 (enExample) | ||
| RU2489148C2 (ru) | Ингибитор активации stat3/5 | |
| RU2348627C2 (ru) | Ингибиторы тирозинкиназ | |
| US5958950A (en) | Benzimidazole compounds useful for the treatment of inflammatory disease, atherosclerosis, restenosis or inhibiting lipoxygenase | |
| RU2386620C2 (ru) | Производные пиридазин-3(2н)-она и их применение в качестве ингибиторов фдэ4 | |
| CN100383124C (zh) | 作为npy拮抗剂的喹啉衍生物 | |
| JP2008513515A5 (enExample) | ||
| JP2020521740A5 (enExample) | ||
| RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| JP2007231005A5 (enExample) | ||
| JP2008513516A5 (enExample) | ||
| ZA200007076B (en) | A pharmaceutical combination comprising a COX-2 inhibitor and iNOS inhibitor. | |
| JP2002030084A5 (enExample) | ||
| CN104940200A (zh) | 多取代芳族化合物作为凝血酶的抑制剂 | |
| JP2004525951A5 (enExample) | ||
| JP2006206609A5 (enExample) | ||
| JP2005529926A5 (enExample) | ||
| JP2007502265A5 (enExample) | ||
| JP2008515913A5 (enExample) | ||
| JP2012507535A5 (enExample) | ||
| JP2008520637A5 (enExample) | ||
| CA2730471A1 (en) | Piperazine derivatives used as cav2.2 calcium channel modulators | |
| JP2006526596A5 (enExample) | ||
| CA2504907A1 (en) | Indoles useful in the treatment of androgen-receptor related diseases | |
| JP2004507527A5 (enExample) |